Eli Lilly Becomes First Health-Care Giant to Hit $1 Trillion on Soaring Drug Success

You are currently viewing Eli Lilly Becomes First Health-Care Giant to Hit $1 Trillion on Soaring Drug Success

Prime Highlights

  • Eli Lilly became the first health-care company in the world to reach a $1 trillion market value.
  • The company’s success is mainly driven by strong demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro.

Key Facts

  • Mounjaro generated $6.52 billion in revenue in the latest quarter, a 109% increase from the previous year, while Zepbound brought in $3.59 billion, up 184%.
  • Experts predict the global weight-loss drug market could exceed $150 billion by the early 2030s.

Background:

Eli Lilly made history by briefly reaching a $1 trillion market value, becoming the first health-care company to join a group usually led by big technology firms. The pharmaceutical leader’s rapid rise has been fueled by extraordinary demand for its blockbuster weight-loss injection Zepbound and diabetes treatment Mounjaro, both of which have transformed the company’s financial performance and market position.

The company’s shares surged in early trading on Friday, touching the trillion-dollar valuation before settling at around $1,048 per share. Eli Lilly now stands alongside elite U.S. corporations such as Apple and Microsoft, and joins Berkshire Hathaway as only the second non-technology company in the United States to reach the milestone.

Much of Eli Lilly’s momentum is driven by the soaring global appetite for GLP-1-based drugs, a market in which it now leads alongside rival Novo Nordisk. In the most recent quarter, Mounjaro generated $6.52 billion in revenue, a 109% jump from the previous year. Zepbound followed with an equally impressive $3.59 billion, up 184% year over year.

Analysts expect demand to keep rising as more approvals are granted and insurance providers begin covering the treatments more widely. Eli Lilly is also developing a pill version of its treatment, which may be easier for patients to take and simpler for the company to make.

Experts say the weight-loss drug market could grow to over $150 billion by the early 2030s, giving Eli Lilly a strong advantage in the long run. While companies like Novo Nordisk and Pfizer are also expanding in this space, Eli Lilly’s new drugs and fast growth have made it a major leader in one of the fastest-growing areas of modern health care.